Albany Molecular Research Inc (AMRI)

21.77
0.04 0.18
NASDAQ : Health Care
Prev Close 21.73
Open 21.73
Day Low/High 21.70 / 21.77
52 Wk Low/High 12.45 / 22.48
Volume 155.81K
Avg Volume 1.37M
Exchange NASDAQ
Shares Outstanding 42.96M
Market Cap 931.85M
EPS -1.80
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Short Interest In Albany Molecular Research Declines 10.6%

The most recent short interest data has been released for the 06/15/2017 settlement date, which shows a 724,231 share decrease in total short interest for Albany Molecular Research Inc , to 6,123,233, a decrease of 10.58% since 05/31/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

INVESTOR ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of Albany Molecular Research, Inc. And Encourages Investors To Contact The Firm For Additional Information

The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Albany...

The Law Offices Of Vincent Wong Reminds Investors Of An Investigation Of Albany Molecular Research, Inc. In Connection With The Sale Of The Company To GTCR LLC And The Carlyle Group

The Law Offices of Vincent Wong are investigating the Board of Directors of Albany Molecular Research, Inc.

The Law Offices Of Vincent Wong Notifies Investors Of An Investigation Of Albany Molecular Research, Inc. In Connection With The Sale Of The Company To GTCR LLC And The Carlyle Group

The Law Offices of Vincent Wong are investigating the Board of Directors of Albany Molecular Research, Inc.

SHAREHOLDER ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of Albany Molecular Research, Inc. And Encourages Investors To Contact The Firm For Additional Information

The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Albany...

INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors Of An Investigation Concerning Whether The Sale Of Albany Molecular Research, Inc. To The Carlyle Group And GTCR LLC Is Fair To Shareholders

The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Albany Molecular Research, Inc.

Albany Molecular Research, Inc. Shareholder Alert: Former SEC Attorney Willie Briscoe Investigates Merger With The Carlyle Group

Former United States Securities and Exchange Commission attorney Willie Briscoe is investigating potential claims against the Board of Directors of Albany Molecular Research, Inc.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces An Investigation Concerning Whether The Sale Of Albany Molecular Research, Inc. To The Carlyle Group And GTCR LLC Is Fair To Shareholders

The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Albany Molecular Research, Inc.

Biotech Movers: Albany Molecular Shares Soar on Sale to PE Firms

Biotech Movers: Albany Molecular Shares Soar on Sale to PE Firms

Albany Molecular Research, Acorda Therapeutics and PTC Therapeutics were among the biotech stock movers in premarket trading on Tuesday.

First Week of June 16th Options Trading For Albany Molecular Research (AMRI)

Investors in Albany Molecular Research Inc saw new options begin trading this week, for the June 16th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the AMRI options chain for the new June 16th contracts and identified one put and one call contract of particular interest.

Denovo Biopharma Obtains Exclusive License To Liafensine From AMRI

- Denovo Biopharma gains an exclusive license to all rights to develop, manufacture and commercialize liafensine globally

First Week Of May 19th Options Trading For Albany Molecular Research (AMRI)

Investors in Albany Molecular Research Inc saw new options become available this week, for the May 19th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the AMRI options chain for the new May 19th contracts and identified one put and one call contract of particular interest.

Albany Molecular Research Becomes Oversold (AMRI)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Oversold Conditions For Albany Molecular Research

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

TheStreet Quant Rating: C (Hold)